UnitedHealth Earnings Lifted by Margin Gains, Raises Outlook
UnitedHealth earnings showed Q1 margin gains and $8.9B cash flow, and the firm raised FY2026 adjusted EPS guidance to >$18.25 to support buybacks.

KEY TAKEAWAYS
- Q1 revenue $111.7B and adjusted EPS $7.23.
- Medical-care ratio improved 90 bps to 83.9%, easing margin pressure.
- Company raised FY2026 adjusted EPS guidance to >$18.25 and authorized $2.0B buybacks.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
UnitedHealth Group reported quarterly results and raised its full-year profit outlook on April 21, 2026, as earnings reflected margin expansion and Optum adjustments the company said should support cash flow and planned buybacks.
Quarterly Results and Outlook
UnitedHealth said consolidated first-quarter 2026 revenues rose 2% to $111.7 billion from $109.6 billion a year earlier. GAAP earnings per share were $6.90, with adjusted earnings per share of $7.23. Earnings from operations totaled $9.0 billion, slightly below $9.1 billion in the prior year, producing a consolidated net margin of 5.6%, down from 5.7%.
The medical-care ratio improved 90 basis points to 83.9%, driven by medical-cost management and favorable reserve development despite elevated utilization and unit costs. This figure included a 20-basis-point benefit from an Optum Health loss-contracts reserve. Operating costs rose, pushing the operating-cost ratio to 13.8% from 12.4%, reflecting investments in personnel, processes, technology, artificial intelligence, and enhancements to consumer and provider experiences.
UnitedHealthcare generated $86.3 billion in revenue, up from $84.6 billion, serving about 49.1 million people. Its operating margin increased 40 basis points to 6.6%. Employer & Individual revenue reached $20.1 billion with 415,000 additional people served. Medicare & Retirement revenue rose 1% to $42.1 billion despite a decline of 965,000 seniors served. Community & State revenue grew 4% to $24.1 billion, with 220,000 fewer people served.
The company raised its full-year 2026 outlook, expecting adjusted net earnings per share above $18.25 and GAAP net earnings per share above $17.35. Cash flows from operations reached $8.9 billion, about 1.4 times net income, while the debt-to-capital ratio stood at 42.9% as of March 31, 2026.
Optum Restructuring and Capital Returns
Optum reported $63.7 billion in revenue, slightly down from $63.9 billion a year earlier, with operating earnings of $3.3 billion. Its segment margin fell to 5.2% from 6.1%. Optum Health revenue declined 3% to $24.1 billion, with operating earnings of $1.1 billion, or $1.3 billion excluding loss-contracts reserve and restructuring charges. Optum Insight posted $5.1 billion in revenue and $1.0 billion in operating earnings. Optum Rx revenue rose 2% to $35.7 billion, with operating earnings of $1.2 billion and 383 million adjusted prescriptions, down from 408 million.
UnitedHealth completed the sale of Optum UK and directed roughly $400 million of net proceeds to the United Health Foundation. It authorized at least $2.0 billion in share repurchases to be completed by June 30, 2026. These moves follow a broader restructuring initiated in the second half of 2025 that refocused the company on U.S. health care, exited non-U.S. businesses, refreshed nearly half of the top 100 leadership roles, and increased investments in artificial intelligence, cybersecurity, prior authorization, transparency, and pharmacy initiatives. Chief Executive Stephen Hemsley said, “We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity.”
Execution of the share repurchase program and further updates tied to the guidance will be key near-term indicators of whether the margin improvement and cash-flow strength persist.





